National Aids Council (nac),

The National AIDS Council (NAC) of Zimbabwe is a statutory body established through the National AIDS Council Act Chapter 15:14 of 2000. Its primary mandate is to coordinate and facilitate the national multi-sectoral response to HIV and AIDS, ensuring a unified and effective approach to combating the epidemic. Additionally, NAC administers the National AIDS Trust Fund (NATF), which is financed through the AIDS Levy—a 3% deduction from every worker's taxable income (PAYE) and corporate tax.

Headquartered at 100 Central Avenue, Harare, Zimbabwe, NAC operates under the Ministry of Health and Child Care. While it functions as an independent entity, it collaborates closely with various government departments, non-governmental organizations, and international partners to implement HIV and AIDS programs across the country. NAC's role in Zimbabwe's pharmaceutical distribution is multifaceted, encompassing the procurement, distribution, and monitoring of antiretroviral therapies (ART) and other essential medications. By managing the National AIDS Trust Fund, NAC ensures the availability and accessibility of these medications to individuals living with HIV, thereby playing a crucial role in the national healthcare system. (nac.org.zw)

NAC's distribution network is designed to ensure the efficient delivery of HIV and AIDS-related medications throughout Zimbabwe. While specific details about warehouse locations and logistics capabilities are not publicly disclosed, NAC's operations are structured to cover all provinces, facilitating nationwide access to essential treatments. The council's distribution strategy likely involves partnerships with local health facilities, regional warehouses, and transportation providers to maintain a steady supply chain. This comprehensive network ensures that antiretroviral therapies and other critical medications reach healthcare centers, clinics, and pharmacies, thereby supporting the treatment needs of individuals living with HIV across the country. (nac.org.zw)

In Zimbabwe's pharmaceutical supply chain, the National AIDS Council (NAC) functions as a central procurement and distribution entity, primarily focusing on HIV and AIDS-related medications. While it does not operate as a traditional wholesaler or distributor for the broader pharmaceutical market, NAC's specialized role is critical in ensuring the availability of antiretroviral therapies (ART) and other essential drugs for HIV treatment. By managing the National AIDS Trust Fund and coordinating with various stakeholders, NAC ensures that these medications are accessible to healthcare providers and patients nationwide. This targeted approach underscores NAC's pivotal position in addressing the HIV epidemic through effective medication distribution and access. (nac.org.zw)

NAC's sourcing strategy for antiretroviral therapies (ART) reveals a concentrated procurement pattern, with a total import value of $200,000 USD from India over four shipments. The top two imported products—Emtricitabine and Tenofovir—each account for $100,000 USD, representing 50% of the total import value. This indicates a strategic focus on these specific ART medications, which are essential components of combination therapy for HIV treatment.

The 100% concentration of imports in these two products suggests a deliberate sourcing decision, possibly to streamline procurement processes and ensure consistent supply. However, this approach also introduces a dependency on a limited number of suppliers, which could pose risks in the event of supply chain disruptions or regulatory changes. The stability of NAC's relationship with Indian suppliers is crucial to mitigate potential challenges. Given the strategic importance of these medications in HIV treatment regimens, maintaining a reliable and uninterrupted supply chain is essential for the council's mission to provide effective care to individuals living with HIV in Zimbabwe.

The resilience of NAC's supply chain for antiretroviral therapies (ART) imported from India is a critical factor in ensuring uninterrupted access to essential HIV medications. While specific details about backup suppliers and formulation diversity are not publicly available, the council's procurement strategy appears to focus on a limited range of ART products—Emtricitabine and Tenofovir. This concentrated sourcing approach may enhance procurement efficiency but could also expose NAC to risks associated with supply chain disruptions, such as manufacturing delays, shipping challenges, or regulatory changes in the supplier country.

To bolster supply chain resilience, it would be prudent for NAC to consider diversifying its supplier base and exploring alternative sources for these critical medications. Additionally, establishing contingency plans and maintaining open communication channels with suppliers can help mitigate potential disruptions. Ensuring that all imported ART products comply with Zimbabwe's regulatory standards, as enforced by the Medicines Control Authority of Zimbabwe (MCAZ), is also essential to maintain the quality and safety of the medications. (mcaz.co.zw)

NAC's concentrated sourcing pattern for antiretroviral therapies (ART) from India positions the council to benefit from streamlined procurement processes and potentially favorable pricing. This strategic focus allows NAC to maintain a consistent supply of essential HIV medications, which is vital for the effective treatment of individuals living with HIV in Zimbabwe.

For Indian exporters, this concentrated sourcing presents an opportunity to strengthen their partnerships with NAC by ensuring reliable supply and compliance with Zimbabwe's regulatory standards. By meeting the council's specific requirements and maintaining consistent product quality, Indian suppliers can solidify their position as preferred partners in NAC's procurement strategy. This collaboration not only supports NAC's mission to combat HIV and AIDS but also opens avenues for sustained business relationships in the Zimbabwean market.

The Medicines Control Authority of Zimbabwe (MCAZ) is the statutory body responsible for regulating and controlling the quality, safety, and efficacy of medicines and allied substances in Zimbabwe. Established by the Medicines and Allied Substances Control Act (MASCA) [Chapter 15:03], MCAZ's mandate includes ensuring that all medicines and medical devices available in the country meet prescribed standards. (mcaz.co.zw)

For Indian pharmaceutical companies seeking to export antiretroviral therapies (ART) to Zimbabwe, obtaining marketing authorization from MCAZ is a critical step. This process involves submitting comprehensive documentation that demonstrates the product's compliance with MCAZ's regulatory requirements, including evidence of safety, efficacy, and quality. The approval pathway is designed to protect public health by ensuring that all imported medicines meet the necessary standards before they are distributed within Zimbabwe.

Import licensing requirements for pharmaceutical products in Zimbabwe are governed by the Medicines Control Authority of Zimbabwe (MCAZ). Indian exporters must obtain an import license from MCAZ to legally supply antiretroviral therapies (ART) to the Zimbabwean market. This license is contingent upon the submission of detailed product dossiers that include information on manufacturing processes, quality control measures, and clinical data supporting the product's safety and efficacy.

Additionally, MCAZ requires that all imported pharmaceutical products be manufactured in facilities that adhere to Good Manufacturing Practice (GMP) standards. Recognition of GMP certifications from reputable authorities, such as the European Union (EU) GMP, World Health Organization (WHO) GMP, or Pharmaceutical Inspection Co-operation Scheme (PIC/S), is essential for the approval process. Indian exporters should ensure that their manufacturing facilities are compliant with these standards to facilitate the importation of ART into Zimbabwe.

To meet the regulatory standards set by the Medicines Control Authority of Zimbabwe (MCAZ), imported antiretroviral therapies (ART) must undergo batch testing to verify their quality, safety, and efficacy. This testing ensures that each batch of medication complies with the specifications outlined in the product's registration dossier.

Stability requirements are also a critical consideration, as they determine the shelf life and storage conditions of the ART products. Manufacturers must provide stability data that supports the product's intended shelf life under specified storage conditions.

Labeling requirements include the use of English as the primary language for all labeling and packaging materials. This ensures that healthcare providers and patients can accurately interpret product information. Additionally, serialization mandates may be implemented to enhance traceability and prevent counterfeit products from entering the supply chain. Indian exporters should familiarize themselves with MCAZ's specific labeling and serialization requirements to ensure compliance and facilitate the smooth importation of ART into Zimbabwe.

Between 2024 and 2026, the Medicines Control Authority of Zimbabwe (MCAZ) has implemented several policy changes affecting the importation of pharmaceutical products, including antiretroviral therapies (ART). These changes aim to strengthen the regulatory framework and enhance the quality assurance of imported medicines.

One significant development is the introduction of stricter pharmacovigilance requirements for marketing authorization holders. Circular 3 of 2022 imposes additional obligations on importers to monitor and report adverse drug reactions, thereby improving patient safety. (portal.mcaz.co.zw)

Furthermore, MCAZ has updated its guidelines on Good Manufacturing Practice (GMP) compliance, emphasizing the need for imported products to meet internationally recognized standards. This includes greater scrutiny of manufacturing facilities and the implementation of more rigorous quality control measures.

These regulatory changes underscore the importance for Indian exporters to stay informed about MCAZ